FMFlorent Mouliere

Florent Mouliere

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Florent Mouliere has a total of 541 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cell-free DNA genomic and fragmentomic features for early outcome prediction in large B cell lymphoma

    by Steven Wang, Parisa Mapar, Norbert Moldovan, Ymke van der Pol, Aram Safrastyan, Erik van Werkhoven, Normastuti Adhini Tantyo, Bart Snieder, André F. Do Brito Valente, A. Vera de Jonge, et al.

  • Open Access

    Ouro-seq: Improved Recovery of Full-Length circRNAs from Samples with Limited RNA Content

    by Birgit M.M. Wever, Yara van Den Burgt, Florent Mouliere, D. Michiel Pegtel, Maaike C.G. Bleeker, Renske D.M. Steenbergen, Norbert Moldovan

    Summary: Circular RNAs (circRNAs) are an emerging class of RNAs with biomarker potential, but their detection in liquid biopsies is challenging due to low abundance. We developed Ouro-seq, a novel long-read sequencing protocol optimized for full-length circRNA recovery. Applied to urine, cervico-vaginal self-samples from cervical cancer patients, and plasma from lung cancer patients and controls, Ouro-seq recovered 2-5 times more and substantially longer circRNA molecules than conventional methods. Plasma contained predominantly exonic circRNAs, while urine and cervico-vaginal samples were dominated by previously undercharacterized intergenic circRNAs. We also identified extensive alternative circularization and splicing events. Functional analysis revealed distinct specialization patterns: exonic circRNAs showed enhanced miRNA sponging potential, while circRNAs from unplaced genomic scaffolds demonstrated greater peptide-coding capacity. This study establishes Ouro-seq as a valuable tool for comprehensive circRNA characterization in low-yield clinical samples and advances circRNA biology understanding with potential biomarker discovery and disease monitoring applications. Motivation: While circular RNAs (circRNAs) constitute a minor fraction of total RNA, they may play critical roles in cancer development. CircRNA concentrations are typically too low for detection by Oxford Nanopore Long-Read Sequencing (LRS), particularly in samples with limited RNA content, such as liquid biopsies. Consequently, LRS-based circRNA analysis from liquid biopsies remains unexplored. To overcome these technical limitations, we developed an optimized circRNA enrichment method utilizing short-amplicon suppression, enabling circRNA profiling from urine, plasma, and cervico-vaginal samples.

  • Open Access

    Noninvasive MRD monitoring and profiling of clonal evolution by ctDNA in patients with advanced cancers treated within molecular tumor boards

    by Lavanya Ranganathan, Julia C. Kuehn, Christian Klingler, Thomas Pauli, Patrick Metzger, Sabine Bleul, Ulrike Philipp, Fabian Hummel, Samuel Weinschenk, Max Deuter, et al.

    Circulating tumor DNA (ctDNA) from blood plasma has emerged as a promising biomarker for noninvasive profiling of tumor mutational landscapes and disease monitoring across cancers. In this study, we developed a targeted next-generation sequencing approach to explore the role of ctDNA for comprehensive tumor genotyping, early response prediction, and characterization of clonal heterogeneity in patients with advanced and rare cancers treated within molecular tumor boards. We applied our technology to 157 plasma specimens from 57 patients at distinct disease milestones and detected tumor variants in 96% of baseline samples, with 65% of them harboring actionable aberrations. Longitudinal monitoring of baseline mutations in on-treatment plasma revealed that ctDNA dynamics were significantly associated with clinical outcomes and enabled early prediction of disease progression. Finally, we observed substantial clonal heterogeneity over time, identifying emerging mutations in all analyzed plasma samples obtained at progression, including potentially targetable variants for subsequent personalized therapies.


  • Open Access

    Cell-Free DNA Genomic and Fragmentomic Features for Early Outcome Prediction in Large B-Cell Lymphoma.

    by Steven Wang, Parisa Mapar, Norbert Moldovan, Ymke van der Pol, Aram Safrastyan, Erik van Werkhoven, Normastuti Adhini Tantyo, Bart Snieder, Andre F. Do Brito Valente, A. Vera de Jong, et al.

    Curative-intent immunochemotherapy fails in ~30% of patients with large B-cell lymphoma (LBCL), yet no validated molecular tool enables early identification of high-risk individuals to guide treatment intensification. Using shallow whole genome sequencing (sWGS) of plasma cell-free DNA from 190 LBCL patients, we developed and validated the ACT score (Aberrations, fragment Composition, Terminal motifs), a composite classifier integrating genomic and fragmentomic features from a single post-cycle-1 sample. ACT-positive patients had worse 2-year outcomes versus ACT-negative patients: time-to-progression 29% vs. 83% (HR 4.4, 95% CI 1.9 − 10.0; P = 1.5 × 10 − 4) and overall survival 47% vs. 93% (HR 8.7, 95% CI 3.0 − 25.4; P = 1.8 × 10−6). ACT score was independently prognostic of the International Prognostic Index, and their combination identified the highest-risk patients. Unlike mutation-based approaches, this assay requires neither tumor tissue, germline control nor a baseline plasma sample. Built on open-source tools and sWGS, the ACT score offers a feasible scalable strategy for early risk stratification in aggressive LBCL.

  • Top Cited Papers

    Advancing the applications of liquid biopsies in oncology

    by Sara Valpione, Alexandra Clipson, Dominic G. Rothwell, Caroline Dive, Florent Mouliere

    Liquid biopsies are increasingly important tools for precision oncology. Although their ability to detect the minute amounts of cancer biomarkers present in biofluids is improving, limitations remain regarding accurate detection of certain pathologies, analytical validation, application range and broad clinical utility. Emerging methods harness multi-omic data from a range of circulating analytes that can be released from various sources via distinct biological processes, thereby providing complementary and more sensitive information. Modulating the cellular release of these analytes and their half-lives in blood can be exploited to inform on cancer detection, treatment selection, response and/or toxicity. Simultaneously, efforts to miniaturize liquid biopsies to capitalize on their minimally invasive nature will accelerate turnaround time and enable continuous and ideally remote monitoring of circulating analytes. Together, these advances towards next-generation liquid biopsies will substantially improve patient experience.


  • Open Access

    Use of circulating tumour DNA to prospectively guide a switch from targeted to immune therapy in BRAF mutant advanced melanoma: the randomised phase II CAcTUS trial

    by Rebecca J. Lee, Dominic G. Rothwell, Nigel Smith, Shien Chow, Juan Delgado-SanMartin, Hitesh Mistry, Yvonne Sylvestre, Shih-Chieh Chiang, Harry Clarke, Gabriela Gremel, et al.

    Checkpoint inhibitor immunotherapy (CPI) for BRAF mutant advanced melanoma first-line results in a better long-term survival compared to targeted therapy (TT), however TT induction may benefit poor prognosis groups. The parallel-arm, randomised phase II, multicentre, feasibility CAcTUS trial (Clinicaltrials.gov NCT03808441) randomised 21 patients to receive standard of care investigators choice TT or CPI, switching to the alternative upon progression ( n = 10), or commencing TT and switching to CPI upon an ≥80% reduction of BRAF variant allele frequency ( VAF) in circulating tumour DNA (ctDNA; n = 11). The study achieved its primary endpoints with 100% (95% confidence interval [CI]: 94-100%) of critical results provided within 7 days to inform a decision to switch and 100% of patients commencing TT achieving an ≥80% reduction of BRAF VAF (95% CI: 80-100%). Secondary outcomes included progression-free survival and overall survival. No new safety signals were observed for TT/CPI. Post-hoc analysis of clinical features, circulating cytokines and chemokines at ctDNA nadir following TT induction suggested a more favourable profile prior to CPI initiation. Longitudinal ctDNA dynamics revealed ctDNA provided an early signal of CPI benefit and that rechallenge with TT following CPI progression resulted in a further ctDNA response. These data support the utility of ctDNA to guide treatment decision-making within a clinically relevant timeframe to optimise treatment scheduling strategies.


  • Etude de la structure et de l'origine des ADN circulants : application à la mise au point d'un test de détection des mutations KRAS et BRAF dans le cancer colorectal

    by Florent Moulière

    Les ADN circulants extracellulaires (ADNcf) sont considérés comme des biomarqueurs potentiels non invasifs de la progression tumorale. Ils présentent l'avantage d'être porteurs des altérations génétiques des tumeurs dont ils sont issus. Les connaissances sur les formes, les mécanismes de libération et les actions biologiques des ADNcf sont cependant encore peu caractérisées.Nous avons émis l'hypothèse que se focaliser sur l'étude de la structure et des origines des ADNcf issus des tumeurs permettrait d'ouvrir de nouvelles perspectives d'applications en génomique personnalisée.Nos travaux ont démontré à l'aide d'un animal modèle que les ADNcf issus des tumeurs de cancers colorectaux sont hautement fragmentés à des tailles inférieures à 145 bp. Cette observation a été confirmée sur plasma humain en réalisant par AFM la première image directe d'ADNcf issu de tumeurs. Nous avons déterminé que les proportions d'ADNcf mutés varient fortement dans la circulation sanguine, mais que près d'un tiers des individus présentaient des proportions d'ADNcf mutés supérieures à 25 % de tous les ADNcf retrouvés dans le sang. Ces découvertes nous ont permis de participer au développement d'une méthode d'analyse spécifique des ADNcf du plasma permettant de déterminer par Q-PCR la concentration en ADNcf, sa fragmentation ainsi que la présence des mutations KRAS et BRAF. Cette méthode a été validée cliniquement sur 79 échantillons de patients atteints de cancer colorectal métastatique en la comparant avec une concordance de 96 % à la technique de référence clinique utilisant l'ADN de tissu tumoral. L'utilisation des ADNcf en tant que « biopsie liquide » devrait être un biomarqueur central dans l'approche de génomique personnalisée des années à venir et les résultats de ces travaux de thèse participer au développement de cette nouvelle approche.

  • Open Access

    Cell-free DNA methylome and fragmentome analysis for relapse monitoring of Ewing sarcoma

    by Sophie A Richardson, Aram Safrastyan, Mina Karimpour, Gayatri Gulati, Patrick J B Harker, Alan Redfern, Simon P Pearce, Vsevolod J Makeev, Bernadette Brennan, Alexander T J Lee, et al.

    Liquid biopsies and cell-free DNA (cfDNA) offer minimally invasive methods for the diagnosis and monitoring of Ewing Sarcoma (EwS). EwS have a low tumour mutational burden and their detection with plasma cfDNA is challenging. We hypothesised that analysing the cfDNA methylome and fragmentome could enhance sensitivity for detecting EwS and identifying disease recurrence. Using T7-MBD-seq, we conducted whole-genome and methylome sequencing of cfDNA from 87 serial samples of 23 patients with EwS and 3 patients with CIC-rearranged sarcoma (CIC). With EwingSign, a new machine learning model, we identified EwS or CIC in a test set for 11 out of 16 patients at diagnosis and 15 out of 18 clinically confirmed relapse events. 0 out of 24 non-cancer controls (NCC) were detected positive with EwingSign. When combined with global and regional fragmentome analysis, all 18 relapse cases were detected, with 15/18 detected by 2 or more modalities, and 1 out of 24 NCC was detected by one modality. These findings indicate that cfDNA methylome and fragmentome analysis, if validated in a larger cohort, could improve disease detection, monitoring and relapse identification in patients with EwS.


  • Open Access

    Improving cell-free DNA detection in advanced-stage high-grade serous ovarian cancer using combined TP53 mutational status and copy number changes

    by Hein S. Zelisse, Ymke van der Pol, Florent Mouliere, Frederike Dijk, Johannes B.G. Halfwerk, Banafsche Mearadji, Ludo F.M. Beenen, Roy J. Reinten, Saskia A.G.M. Cillessen, Gerrit K.J. Hooijer, et al.


  • Open Access

    Cell-free DNA methylome and fragmentome analysis for disease relapse monitoring in patients with Ewing Sarcoma

    by Sophie A. Richardson, Gayatri Gulati, Patrick J.B. Harker, Alan Redfern, Simon P. Pearce, Mina Karimpour, Steven M. Hill, Vsevolod J. Makeev, Bernadette Brennan, Alexander Tj Lee, et al.

    Summary: Liquid biopsies and cell-free DNA (cfDNA) offer minimally invasive methods for the diagnosis and monitoring of Ewing Sarcoma (EwS). EwS have a low tumour mutational burden and their detection with plasma cfDNA is challenging. We hypothesised that analysing the cfDNA methylome and fragmentome could enhance sensitivity for detecting EwS and identifying early disease recurrence. We conducted whole-genome and methylome sequencing of cfDNA from 68 serial samples of 15 patients with EwS and 3 patients with CIC-rearranged sarcoma (CIC). With EwingSign, a new machine learning model, we identified EwS or CIC in a test set for 10 out of 12 patients at diagnosis and 15 out of 18 clinically confirmed relapse events. 0 out of 29 non-cancer controls were detected positive with EwingSign. These findings indicate that cfDNA methylome and fragmentome analysis, if validated in a larger cohort, could improve disease detection, monitoring and relapse identification in patients with EwS.